EGFR and non-small cell lung carcinoma: For NSCLC patients carrying EGFR gene mutations, the main clinical treatment is currently TKIs, such as the first-generation TKIs gefitinib, erlotinib and icotinib; the second-generation TKIs afatinib and dacomitinib; and the third-generation TKI osimertinib [18–22].